Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Contraception and Contraceptive Drugs

Free Subscription Articles published in Gynecol Endocrinol Retrieve available abstracts of 53 articles: HTML format

Single Articles

December 2024
1. COSAR A, Ozcan P, Tanoglu FB, Tok OE, et al
   Comparative effects of the antioxidant glutathione with metformin and Diane-35 on hormonal, metabolic, and inflammatory indicators in a DHEA-induced PCOS rat model.
   Gynecol Endocrinol. 2024;40:2302086.
   PubMed     Abstract available
   
   
   
2. HAN SJ, Kim H, Ku SY, Suh CS, et al
   Comparison of resumption of ovulation after cessation of oral contraceptives and medroxyprogesterone acetate in women with polycystic ovary syndrome.
   Gynecol Endocrinol. 2024;40:2309349.
   PubMed     Abstract available
   
   
   
3. LA TORRE F, Vannuccini S, Toscano F, Gallucci E, et al
   Long-term treatment for endometriosis with dienogest: efficacy, side effects and tolerability.
   Gynecol Endocrinol. 2024;40:2336121.
   PubMed     Abstract available
   
   
   December 2023
4. FARRIS M, Arisi E, Mirjalili N, Nappi RE, et al
   Attitudes of women and pharmacists on the opportunity to obtain a progestogen-only pill over the counter - Italian outcomes.
   Gynecol Endocrinol. 2023;39:2206922.
   PubMed     Abstract available
   
   
   
5. GENAZZANI AR, Fidecicchi T, Arduini D, Giannini A, et al
   Hormonal and natural contraceptives: a review on efficacy and risks of different methods for an informed choice.
   Gynecol Endocrinol. 2023;39:2247093.
   PubMed     Abstract available
   
   
   
6. NAPPI RE, Farris M, Gallina Toschi A, Michieli R, et al
   Overcoming barriers to oral contraception in Italy an expert opinion to empower women.
   Gynecol Endocrinol. 2023;39:2254400.
   PubMed     Abstract available
   
   
   
7. PALACIOS S, Ayala G, Gonzalez G, Badilla-Apuy CL, et al
   Combined oral contraceptives: update recommendations of the Latin American contraceptive association.
   Gynecol Endocrinol. 2023;39:2271072.
   PubMed     Abstract available
   
   
   
8. QI Q, Xia Y, Luo J, Wang Y, et al
   Cocktail treatment by GnRH-antagonist, letrozole, and mifepristone for the prevention of ovarian hyperstimulation syndrome: a prospective randomized trial.
   Gynecol Endocrinol. 2023;39:2269281.
   PubMed     Abstract available
   
   
   October 2023
9. TAHARA N, Ito F, Kawamata M, Otani M, et al
   Dienogest does not augment the gene expression of adhesion molecules, MCP-1, and monocyte adherence in human endothelial cells.
   Gynecol Endocrinol. 2023;40:2270621.
   PubMed     Abstract available
   
   
   June 2023
10. PINGARRON SANTOFIMIA C, Poyo Torcal S, Lopez Verdu H, Henriquez Linares A, et al
    Evaluation of the efficacy of an antioxidant combination for the modulation of metabolic, endocrine, and clinical parameters in patients with polycystic ovary syndrome.
    Gynecol Endocrinol. 2023;39:2227277.
    PubMed     Abstract available
    
    
    May 2023
11. BOUNOUS VE, Actis S, Rosso R, Giorgi M, et al
    No-daily hormonal contraception today: general overview and application in specific clinical settings.
    Gynecol Endocrinol. 2023;39:2214626.
    PubMed     Abstract available
    
    
    
12. JI L, Jin L, Shao MJ, Hu M, et al
    Levonorgestrel-releasing intrauterine system effects on metabolic variables in PCOS.
    Gynecol Endocrinol. 2023;39:2208667.
    PubMed     Abstract available
    
    
    March 2023
13. NAPPI RE, Tiranini L, Bosoni D, Cucinella L, et al
    Women's attitudes about combined hormonal contraception (CHC) - induced menstrual bleeding changes - influence of personality traits in an Italian clinical sample.
    Gynecol Endocrinol. 2023 Mar 14:2189971. doi: 10.1080/09513590.2023.2189971.
    PubMed     Abstract available
    
    
    January 2023
14. VON STOCKUM S, Becker K, Bauerfeind A, Franke C, et al
    NOMAC-E2 compares to LNG combined oral contraceptives in women over forty: real-world PRO-E2 study.
    Gynecol Endocrinol. 2023 Jan 23:1-5. doi: 10.1080/09513590.2023.2166032.
    PubMed     Abstract available
    
    
    
15. VON STOCKUM S, Bauerfeind A, Becker K, Franke C, et al
    NOMAC-E2 shows a better contraceptive effectiveness than LNG combined oral contraceptives in women under 25: real-world PRO-E2 study.
    Gynecol Endocrinol. 2023 Jan 8:1-6. doi: 10.1080/09513590.2022.2162036.
    PubMed     Abstract available
    
    
    October 2022
16. REGIDOR PA, Colli E
    The progestin-only pills drospirenone 4 mg and desogestrel 0.075 mg as an option for the management of dysmenorrhea and mastodynia.
    Gynecol Endocrinol. 2022 Oct 20:1-5. doi: 10.1080/09513590.2022.2134339.
    PubMed     Abstract available
    
    
    August 2022
17. MIAO J, Lu J, Tang J, Lu P, et al
    Long-term treatment of dienogest with symptomatic adenomyosis: retrospective analysis of efficacy and safety in clinical practice.
    Gynecol Endocrinol. 2022;38:656-660.
    PubMed     Abstract available
    
    
    
18. MIN M, Ruan X, Wang H, Cheng J, et al
    Effect of orlistat during individualized comprehensive life-style intervention on visceral fat in overweight or obese PCOS patients.
    Gynecol Endocrinol. 2022;38:676-680.
    PubMed     Abstract available
    
    
    July 2022
19. GU M, Ruan X, Li Y, Li T, et al
    Effect on the cardiovascular independent risk factor lipoprotein(a) in overweight or obese PCOS patients with ethinyl-estradiol/drospirenone alone or plus orlistat.
    Gynecol Endocrinol. 2022;38:598-602.
    PubMed     Abstract available
    
    
    June 2022
20. OKYAY RE, Cetintas B, Akdoner A, Oztura I, et al
    The effect of oral contraceptive use on sympatic nerve activity in patients with polycystic ovary syndrome.
    Gynecol Endocrinol. 2022 Jun 7:1-6. doi: 10.1080/09513590.2022.2082403.
    PubMed     Abstract available
    
    
    May 2022
21. LEPPANEN R, Tinkanen H, Huhtala H, Ahinko K, et al
    Single-administered GnRH agonist as luteal phase support in insemination cycles: a randomized controlled trial.
    Gynecol Endocrinol. 2022;38:438-442.
    PubMed     Abstract available
    
    
    April 2022
22. REGIDOR PA, Palacios S, Colli E
    Bleeding profile of women with cardiovascular risk factors using a drospirenone only pill with 4 mg over nine cycles compared to desogestrel 0.075 mg.
    Gynecol Endocrinol. 2022;38:333-338.
    PubMed     Abstract available
    
    
    March 2022
23. KIZILKAYA Y, Ibanoglu MC, Kiykac Altinbas S, Engin-Ustun Y, et al
    A prospective study examining the effect of dienogest treatment on endometrioma size and symptoms.
    Gynecol Endocrinol. 2022 Mar 23:1-4. doi: 10.1080/09513590.2022.2053956.
    PubMed     Abstract available
    
    
    
24. VANNUCCINI S, Biagiotti C, Esposto MC, La Torre F, et al
    Long-term treatment of endometriosis-related pain among women seeking hormonal contraception.
    Gynecol Endocrinol. 2022 Mar 3:1-5. doi: 10.1080/09513590.2022.2047172.
    PubMed     Abstract available
    
    
    January 2022
25. TRIGO ACM, Maron CC, Pinheiro MSA, da Silva SBL, et al
    Female sexual function in women using LARC methods.
    Gynecol Endocrinol. 2022;38:68-72.
    PubMed     Abstract available
    
    
    December 2021
26. BUGGIO L, Barbara G, Facchin F, Ghezzi L, et al
    The influence of hormonal contraception on depression and female sexuality: a narrative review of the literature.
    Gynecol Endocrinol. 2021 Dec 16:1-9. doi: 10.1080/09513590.2021.2016693.
    PubMed     Abstract available
    
    
    November 2021
27. JI M, Yuan M, Jiao X, Li Q, et al
    A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea.
    Gynecol Endocrinol. 2021 Nov 9:1-6. doi: 10.1080/09513590.2021.2000961.
    PubMed     Abstract available
    
    
    September 2021
28. FERREIRA-FILHO ES, Bahamondes L, Duarte DC, Guimaraes ALM, et al
    Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report.
    Gynecol Endocrinol. 2021 Sep 6:1-4. doi: 10.1080/09513590.2021.1974380.
    PubMed     Abstract available
    
    
    August 2021
29. REGIDOR PA, Colli E, Palacios S
    Overall and bleeding-related discontinuation rates of a new oral contraceptive containing 4 mg drospirenone only in a 24/4 regimen and comparison to 0.075 mg desogestrel.
    Gynecol Endocrinol. 2021 Aug 17:1-7. doi: 10.1080/09513590.2021.1963432.
    PubMed     Abstract available
    
    
    
30. NIE L, Zou H, Ma X, Cheng L, et al
    A clinical observational study on the efficacy of subcutaneous etonogestrel implants for adenomyosis in 20 patients.
    Gynecol Endocrinol. 2021;37:735-739.
    PubMed     Abstract available
    
    
    June 2021
31. YAO W, Dong X, Yu X, Luo J, et al
    The use of oral contraceptive is inversely associated with the risk of type 2 diabetes mellitus among middle-aged women.
    Gynecol Endocrinol. 2021 Jun 1:1-6. doi: 10.1080/09513590.2021.1932802.
    PubMed     Abstract available
    
    
    May 2021
32. NICOLAS I, Martinez-Zamora MA, Gracia M, Carrion A, et al
    Management of symptomatic uterine fibroids after ulipristal acetate suspension and identification of high risk patients for surgery at 6-months of follow-up.
    Gynecol Endocrinol. 2021 May 28:1-5. doi: 10.1080/09513590.2021.1929152.
    PubMed     Abstract available
    
    
    
33. CECCARONI M, Clarizia R, Liverani S, Donati A, et al
    Dienogest vs GnRH agonists as postoperative therapy after laparoscopic eradication of deep infiltrating endometriosis with bowel and parametrial surgery: a randomized controlled trial.
    Gynecol Endocrinol. 2021 May 26:1-4. doi: 10.1080/09513590.2021.1929151.
    PubMed     Abstract available
    
    
    
34. LI J, Sun Y, Mo S, Wang S, et al
    Effects of oral contraceptive for different responder women before GnRH antagonists: a systematic review and meta-analysis.
    Gynecol Endocrinol. 2021 May 11:1-10. doi: 10.1080/09513590.2021.1918664.
    PubMed     Abstract available
    
    
    March 2021
35. MARIANI LL, Novara L, Mancarella M, Fuso L, et al
    Estradiol/nomegestrol acetate as a first-line and rescue therapy for the treatment of ovarian and deep infiltrating endometriosis.
    Gynecol Endocrinol. 2021 Mar 22:1-4. doi: 10.1080/09513590.2021.1903420.
    PubMed     Abstract available
    
    
    
36. PIACENTI I, Viscardi MF, Masciullo L, Sangiuliano C, et al
    Dienogest versus continuous oral levonorgestrel/EE in patients with endometriosis: what's the best choice?
    Gynecol Endocrinol. 2021 Mar 2:1-5. doi: 10.1080/09513590.2021.1892632.
    PubMed     Abstract available
    
    
    
37. TROIA L, Martone S, Morgante G, Luisi S, et al
    Management of perimenopause disorders: hormonal treatment.
    Gynecol Endocrinol. 2021;37:195-200.
    PubMed     Abstract available
    
    
    February 2021
38. BUYUK GN, Oskovi-Kaplan ZA, Kansu-Celik H, Neselioglu S, et al
    Copper and levonorgestrel containing intrauterine devices: comparison of their effect on oxidative stress markers.
    Gynecol Endocrinol. 2021 Feb 17:1-4. doi: 10.1080/09513590.2021.1878132.
    PubMed     Abstract available
    
    
    
39. CLEMENZA S, Vannuccini S, Capezzuoli T, Meleca CI, et al
    Is primary dysmenorrhea a precursor of future endometriosis development?
    Gynecol Endocrinol. 2021 Feb 11:1-7. doi: 10.1080/09513590.2021.1878134.
    PubMed     Abstract available
    
    
    January 2021
40. ATAKUL T, Tayyar AT, Turan OD, Celik SY, et al
    An assessment of the protective effect of gonadotropin-releasing hormone agonist and antagonist on bleomycin-induced ovarian toxicity in rats.
    Gynecol Endocrinol. 2021;37:46-50.
    PubMed     Abstract available
    
    
    October 2020
41. LI X, Zhang X, Cai J, Pang J, et al
    Granulosa cells apoptosis and follicular fluid hormones: comparison of progestin-primed ovarian stimulation versus GnRH antagonist protocols.
    Gynecol Endocrinol. 2020 Oct 23:1-5. doi: 10.1080/09513590.2020.1822802.
    PubMed     Abstract available
    
    
    June 2020
42. STEFANIAK A, Domitrz J, Siewko K, Szelachowska M, et al
    Pituitary adenoma and apoplexy during GnRH agonist treatment for IVF - case report.
    Gynecol Endocrinol. 2020;36:561-563.
    PubMed     Abstract available
    
    
    May 2020
43. DEL FORNO S, Degli Esposti E, Salucci P, Leonardi D, et al
    Liver function, tolerability and satisfaction during treatment with ulipristal acetate in women with fibroids: a single center experience.
    Gynecol Endocrinol. 2020;36:445-447.
    PubMed     Abstract available
    
    
    April 2020
44. LASORELLA S, Porto R, Iezzi ML, Pistone C, et al
    Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of Central precocious puberty (CPP): a retrospective study.
    Gynecol Endocrinol. 2020;36:338-340.
    PubMed     Abstract available
    
    
    February 2020
45. VIGNALI M, Belloni GM, Pietropaolo G, Barbasetti Di Prun A, et al
    Effect of Dienogest therapy on the size of the endometrioma.
    Gynecol Endocrinol. 2020 Feb 16:1-5. doi: 10.1080/09513590.2020.1725965.
    PubMed     Abstract available
    
    
    December 2019
46. PALAIA I, Del Negro V, Fracassi A, Schiavi M, et al
    Efficacy of ulipristal acetate (UPA) for the treatment of expulsion uterine myomas: report of two cases.
    Gynecol Endocrinol. 2019 Dec 26:1-2. doi: 10.1080/09513590.2019.1707795.
    PubMed     Abstract available
    
    
    
47. XHOLLI A, Filip G, Previtera F, Cagnacci A, et al
    Modification of endometrioma size during hormone therapy containing dienogest.
    Gynecol Endocrinol. 2019 Dec 16:1-5. doi: 10.1080/09513590.2019.1703942.
    PubMed     Abstract available
    
    
    October 2019
48. MATSUSHIMA T, Akira S, Yoneyama K, Takeshita T, et al
    Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest.
    Gynecol Endocrinol. 2019 Oct 29:1-4. doi: 10.1080/09513590.2019.1683818.
    PubMed     Abstract available
    
    
    August 2019
49. PALAIA I, Bardhi E, Boccia SM, Pecorini F, et al
    Severe hemoperitoneum due to endometriosis in a non-pregnant woman under dienogest therapy: a case report.
    Gynecol Endocrinol. 2019 Aug 13:1-2. doi: 10.1080/09513590.2019.1653843.
    PubMed     Abstract available
    
    
    
50. GIARRE G, Franchini M, Castellacci E, Malune ME, et al
    Ulipristal acetate in symptomatic uterine fibroids. A real-world experience in a multicentric Italian study.
    Gynecol Endocrinol. 2019 Aug 8:1-4. doi: 10.1080/09513590.2019.1648419.
    PubMed     Abstract available
    
    
    July 2019
51. BISCIONE A, Barra V, Bellone E, Severi FM, et al
    Ulipristal acetate on quality of life and sexual function of women with uterine fibromatosis.
    Gynecol Endocrinol. 2019 Jul 22:1-6. doi: 10.1080/09513590.2019.1640202.
    PubMed     Abstract available
    
    
    
52. ANGIONI S, Pontis A, Malune ME, Cela V, et al
    Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study.
    Gynecol Endocrinol. 2019 Jul 16:1-3. doi: 10.1080/09513590.2019.1640674.
    PubMed     Abstract available
    
    
    
53. MUZII L, Galati G, Di Tucci C, Di Feliciantonio M, et al
    Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain.
    Gynecol Endocrinol. 2019 Jul 14:1-3. doi: 10.1080/09513590.2019.1640199.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Contraception and Contraceptive Drugs is free of charge.